7. Enter the index of the starting dose level.
**Note:**
Index of
lowest
dose level is always 1. If the design allows for
*'minus'*
dose levels (i.e. -2, -1, etc.), then the index of the starting dose should account for these lower levels (i.e. if -1 dose level allowed, starting dose is 2.)

**This application simulates operating characteristics for the Bayesian continual reassessment method [1] with the following specifications.**

1.
**Skipping Restriction:**
The trial is not allowed to skip dose levels when escalating.

2.
**Skeleton:**
For the specified target DLT rate and total number of dose levels, the skeleton of power model d^exp(a) is generated according to Lee and Cheung (2009) [2] using a prior MTD located at the median dose level and a spacing measure of delta=0.05.

3.
**Prior:**
The prior distribution on the parameter
**a**
is a mean zero normal distribution with the least informative prior variance [3].

4.
**Safety Stopping Rule:**
Stop the trial for safety if the lower limit of an Agresti-Coull binomial confidence interval [4] for the lowest study dose level exceeds the target DLT rate

[1] O'Quigley J, Pepe M, Fisher L (1990). Continual reassessment method: a practical design for phase I clinical trials in cancer,
*Biometrics;*
**46**
(1): 33-48.

[2] Lee and Cheung (2009). Model calibration in the continual reassessment method,
*Clinical Trials;*
**6**
(3): 227-238.

[3] Lee and Cheung (2011). Calibration of prior variance in the bayesian continual reassessment method,
*Statistics in Medicine;*
**30**
(17): 2081-2089.

[3] Agresti A, Coull BA (1998). Approximate is better than 'exact' for interval estimation of binomial proportions,
*American Statistician;*
**52**
: 119-126.

1.Enter the index of the starting dose level.
**Note:**
Index of
lowest
dose level is always 1. If the design allows for
*'minus'*
dose levels (i.e. -2, -1, etc.), then the index of the starting dose should account for these lower levels (i.e. if -1 dose level allowed, starting dose is 2.)

**This application computes a recommended dose level for the next patient in a phase I trial according to the Bayesian continual reassessment method [1] with the following specifications.**

1.
**Skipping Restriction:**
The trial is not allowed to skip dose levels when escalating.

2.
**Skeleton:**
For the specified target DLT rate and total number of dose levels, the skeleton of power model d^exp(a) is generated according to Lee and Cheung (2009) [2] using a prior MTD located at the median dose level and a spacing measure of delta=0.05.

3.
**Prior:**
The prior distribution on the parameter
**a**
is a mean zero normal distribution with the least informative prior variance [3].

4.
**Safety Stopping Rule:**
Stop the trial for safety if the lower limit of an Agresti-Coull binomial confidence interval [4] for the lowest study dose level exceeds the target DLT rate

[1] O'Quigley J, Pepe M, Fisher L (1990). Continual reassessment method: a practical design for phase I clinical trials in cancer,
*Biometrics;*
**46**
(1): 33-48.

[2] Lee and Cheung (2009). Model calibration in the continual reassessment method,
*Clinical Trials;*
**6**
(3): 227-238.

[3] Lee and Cheung (2011). Calibration of prior variance in the bayesian continual reassessment method,
*Statistics in Medicine;*
**30**
(17): 2081-2089.

[4] Agresti A, Coull BA (1998). Approximate is better than 'exact' for interval estimation of binomial proportions,
*American Statistician;*
**52**
: 119-126.

**This application computes the safety stopping bounds for the lowest study dose level based on Agresti-Coull binomial confidence interval estimation [1].**

[1] Agresti A, Coull BA (1998). Approximate is better than 'exact' for interval estimation of binomial proportions,
*American Statistician;*
**52**
: 119-126.